0 XP   0   0   0

Nectar Lifesciences Limited
Buy, Hold or Sell?

Should you buy, hold or sell Nectar Lifesciences Limited?

I guess you are interested in Nectar Lifesciences Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Nectar Lifesciences Limited

Let's start. I'm going to help you getting a better view of Nectar Lifesciences Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Nectar Lifesciences Limited even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Nectar Lifesciences Limited is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Nectar Lifesciences Limited. The closing price on 2023-01-27 was INR20.50 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Nectar Lifesciences Limited Daily Candlestick Chart
Nectar Lifesciences Limited Daily Candlestick Chart
Summary









1. Valuation of Nectar Lifesciences Limited




Current price per share

INR20.50

2. Growth of Nectar Lifesciences Limited




Is Nectar Lifesciences Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$133.8m$130.6m$3.1m2.4%

How much money is Nectar Lifesciences Limited making?

Current yearPrevious yearGrowGrow %
Making money$3m-$9m$12m392.5%
Net Profit Margin1.5%-4.7%--

How much money comes from the company's main activities?

3. Financial Health of Nectar Lifesciences Limited




Comparing to competitors in the Drug Manufacturers - Major industry




  Industry Rankings (Drug Manufacturers - Major)  


Richest
#6 / 12

Most Profit
#11 / 12


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Nectar Lifesciences Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nectar Lifesciences Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Nectar Lifesciences Limited to the Drug Manufacturers - Major industry mean.
  • A Net Profit Margin of 1.5% means that ₹0.02 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nectar Lifesciences Limited:

  • The MRQ is 1.5%. The company is making a profit. +1
  • The TTM is 1.5%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ1.5%TTM1.5%0.0%
TTM1.5%YOY-4.7%+6.2%
TTM1.5%5Y0.5%+1.0%
5Y0.5%10Y1.8%-1.3%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5%10.8%-9.3%
TTM1.5%10.8%-9.3%
YOY-4.7%14.8%-19.5%
5Y0.5%12.2%-11.7%
10Y1.8%11.9%-10.1%
1.1.2. Return on Assets

Shows how efficient Nectar Lifesciences Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nectar Lifesciences Limited to the Drug Manufacturers - Major industry mean.
  • 1.0% Return on Assets means that Nectar Lifesciences Limited generated ₹0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nectar Lifesciences Limited:

  • The MRQ is 1.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.0%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.0%0.0%
TTM1.0%YOY-3.1%+4.1%
TTM1.0%5Y0.6%+0.5%
5Y0.6%10Y1.4%-0.8%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%1.8%-0.8%
TTM1.0%2.3%-1.3%
YOY-3.1%3.0%-6.1%
5Y0.6%3.0%-2.4%
10Y1.4%2.7%-1.3%
1.1.3. Return on Equity

Shows how efficient Nectar Lifesciences Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nectar Lifesciences Limited to the Drug Manufacturers - Major industry mean.
  • 2.3% Return on Equity means Nectar Lifesciences Limited generated ₹0.02 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nectar Lifesciences Limited:

  • The MRQ is 2.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.3%TTM2.3%0.0%
TTM2.3%YOY-6.9%+9.2%
TTM2.3%5Y1.5%+0.8%
5Y1.5%10Y3.6%-2.1%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3%2.5%-0.2%
TTM2.3%3.9%-1.6%
YOY-6.9%4.4%-11.3%
5Y1.5%4.2%-2.7%
10Y3.6%4.0%-0.4%

1.2. Operating Efficiency of Nectar Lifesciences Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nectar Lifesciences Limited is operating .

  • Measures how much profit Nectar Lifesciences Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nectar Lifesciences Limited to the Drug Manufacturers - Major industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nectar Lifesciences Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y5.4%-5.4%
5Y5.4%10Y7.8%-2.5%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.7%-29.7%
TTM-11.5%-11.5%
YOY-11.7%-11.7%
5Y5.4%12.0%-6.6%
10Y7.8%11.0%-3.2%
1.2.2. Operating Ratio

Measures how efficient Nectar Lifesciences Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • An Operation Ratio of 0.82 means that the operating costs are ₹0.82 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 0.821. The company is less efficient in keeping operating costs low.
  • The TTM is 0.821. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.821TTM0.8210.000
TTM0.821YOY0.833-0.012
TTM0.8215Y1.383-0.562
5Y1.38310Y1.494-0.111
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8210.475+0.346
TTM0.8210.425+0.396
YOY0.8330.731+0.102
5Y1.3830.943+0.440
10Y1.4940.983+0.511

1.3. Liquidity of Nectar Lifesciences Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nectar Lifesciences Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • A Current Ratio of 1.35 means the company has ₹1.35 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 1.350. The company is just able to pay all its short-term debts.
  • The TTM is 1.350. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.350TTM1.3500.000
TTM1.350YOY1.043+0.306
TTM1.3505Y1.248+0.102
5Y1.24810Y1.208+0.040
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3501.824-0.474
TTM1.3501.800-0.450
YOY1.0431.807-0.764
5Y1.2481.305-0.057
10Y1.2081.218-0.010
1.3.2. Quick Ratio

Measures if Nectar Lifesciences Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nectar Lifesciences Limited to the Drug Manufacturers - Major industry mean.
  • A Quick Ratio of 0.46 means the company can pay off ₹0.46 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 0.462. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.462. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.462TTM0.4620.000
TTM0.462YOY0.337+0.125
TTM0.4625Y0.410+0.052
5Y0.41010Y0.411-0.001
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4621.248-0.786
TTM0.4621.200-0.738
YOY0.3371.151-0.814
5Y0.4100.836-0.426
10Y0.4110.750-0.339

1.4. Solvency of Nectar Lifesciences Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nectar Lifesciences Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nectar Lifesciences Limited to Drug Manufacturers - Major industry mean.
  • A Debt to Asset Ratio of 0.54 means that Nectar Lifesciences Limited assets are financed with 54.5% credit (debt) and the remaining percentage (100% - 54.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 0.545. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.545. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.545TTM0.5450.000
TTM0.545YOY0.555-0.010
TTM0.5455Y0.574-0.029
5Y0.57410Y0.594-0.020
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5450.415+0.130
TTM0.5450.419+0.126
YOY0.5550.429+0.126
5Y0.5740.455+0.119
10Y0.5940.431+0.163
1.4.2. Debt to Equity Ratio

Measures if Nectar Lifesciences Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nectar Lifesciences Limited to the Drug Manufacturers - Major industry mean.
  • A Debt to Equity ratio of 119.8% means that company has ₹1.20 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 1.198. The company is able to pay all its debts with equity. +1
  • The TTM is 1.198. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.198TTM1.1980.000
TTM1.198YOY1.249-0.051
TTM1.1985Y1.357-0.159
5Y1.35710Y1.478-0.121
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1980.675+0.523
TTM1.1980.698+0.500
YOY1.2490.738+0.511
5Y1.3570.840+0.517
10Y1.4780.814+0.664

2. Market Valuation of Nectar Lifesciences Limited

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Nectar Lifesciences Limited generates.

  • Above 15 is considered overpriced but always compare Nectar Lifesciences Limited to the Drug Manufacturers - Major industry mean.
  • A PE ratio of 21.53 means the investor is paying ₹21.53 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nectar Lifesciences Limited:

  • The EOD is 18.355. Very good. +2
  • The MRQ is 21.533. Very good. +2
  • The TTM is 21.533. Very good. +2
Trends
Current periodCompared to+/- 
EOD18.355MRQ21.533-3.179
MRQ21.533TTM21.5330.000
TTM21.533YOY-5.693+27.227
TTM21.5335Y8.444+13.089
5Y8.44410Y10.381-1.937
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD18.35573.229-54.874
MRQ21.53366.328-44.795
TTM21.53360.797-39.264
YOY-5.69333.289-38.982
5Y8.44460.412-51.968
10Y10.38164.422-54.041
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Nectar Lifesciences Limited.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 9.195. Seems overpriced? -1
  • The TTM is 9.195. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ9.195TTM9.1950.000
TTM9.195YOY2.470+6.725
TTM9.1955Y8.595+0.600
5Y8.59510Y10.981-2.387
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ9.195-0.235+9.430
TTM9.1950.137+9.058
YOY2.4700.124+2.346
5Y8.5950.232+8.363
10Y10.9810.222+10.759

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nectar Lifesciences Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • A PB ratio of 0.50 means the investor is paying ₹0.50 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Nectar Lifesciences Limited:

  • The EOD is 0.423. Very good. +2
  • The MRQ is 0.496. Very good. +2
  • The TTM is 0.496. Very good. +2
Trends
Current periodCompared to+/- 
EOD0.423MRQ0.496-0.073
MRQ0.496TTM0.4960.000
TTM0.496YOY0.393+0.103
TTM0.4965Y0.398+0.098
5Y0.39810Y0.575-0.176
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD0.4231.495-1.072
MRQ0.4961.439-0.943
TTM0.4961.890-1.394
YOY0.3932.460-2.067
5Y0.3981.972-1.574
10Y0.5752.221-1.646
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Nectar Lifesciences Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.1541.1540%-3.304+386%0.724+59%5.390-79%
Book Value Growth--1.0241.0240%0.935+10%1.017+1%1.021+0%
Book Value Per Share--48.51148.5110%47.357+2%48.6030%45.779+6%
Book Value Per Share Growth--1.0241.0240%0.935+10%1.017+1%1.021+0%
Current Ratio--1.3501.3500%1.043+29%1.248+8%1.208+12%
Debt To Asset Ratio--0.5450.5450%0.555-2%0.574-5%0.594-8%
Debt To Equity Ratio--1.1981.1980%1.249-4%1.357-12%1.478-19%
Dividend Per Share--0.0460.0460%0.050-8%0.055-17%0.080-43%
Dividend Per Share Growth--0.9170.9170%0.828+11%0.850+8%0.931-2%
Eps--1.1171.1170%-3.267+393%0.744+50%1.592-30%
Eps Growth--2.3422.3420%-2.305+198%0.512+357%0.683+243%
Free Cash Flow Per Share--3.1233.1230%-0.440+114%4.668-33%4.818-35%
Free Cash Flow Per Share Growth--9.1029.1020%-0.043+100%3.341+172%2.520+261%
Free Cash Flow To Equity Per Share---2.200-2.2000%0.073-3131%-0.686-69%-0.710-68%
Free Cash Flow To Equity Per Share Growth---30.310-30.3100%2.075-1561%-233.041+669%-148.533+390%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--37.475--------
Intrinsic Value_10Y_min--31.917--------
Intrinsic Value_1Y_max--3.267--------
Intrinsic Value_1Y_min--3.174--------
Intrinsic Value_3Y_max--10.187--------
Intrinsic Value_3Y_min--9.614--------
Intrinsic Value_5Y_max--17.557--------
Intrinsic Value_5Y_min--16.090--------
Net Profit Margin--0.0150.0150%-0.047+416%0.005+193%0.018-19%
Operating Margin----0%-0%0.054-100%0.078-100%
Operating Ratio--0.8210.8210%0.833-1%1.383-41%1.494-45%
Pb Ratio0.423-17%0.4960.4960%0.393+26%0.398+24%0.575-14%
Pe Ratio18.355-17%21.53321.5330%-5.693+126%8.444+155%10.381+107%
Peg Ratio--9.1959.1950%2.470+272%8.595+7%10.981-16%
Price Per Share20.500-17%24.05024.0500%18.600+29%19.218+25%25.599-6%
Price To Total Gains Ratio17.089-17%20.04820.0480%-5.716+129%8.066+149%3.827+424%
Profit Growth--2.3422.3420%-2.305+198%0.512+357%0.683+243%
Quick Ratio--0.4620.4620%0.337+37%0.410+13%0.411+12%
Return On Assets--0.0100.0100%-0.031+393%0.006+83%0.014-24%
Return On Equity--0.0230.0230%-0.069+400%0.015+55%0.036-37%
Revenue Growth--1.0811.0810%0.653+66%1.028+5%1.026+5%
Total Gains Per Share--1.2001.2000%-3.254+371%0.780+54%5.470-78%
Total Gains Per Share Growth--2.3692.3690%-2.258+195%0.530+347%1.004+136%
Usd Book Value--133812315.000133812315.0000%130629690.000+2%134067072.6000%126276296.333+6%
Usd Book Value Change Per Share--0.0140.0140%-0.041+386%0.009+59%0.066-79%
Usd Book Value Per Share--0.5970.5970%0.582+2%0.5980%0.563+6%
Usd Dividend Per Share--0.0010.0010%0.001-8%0.001-17%0.001-43%
Usd Eps--0.0140.0140%-0.040+393%0.009+50%0.020-30%
Usd Free Cash Flow----0%-0%-0%-0%
Usd Free Cash Flow Per Share--0.0380.0380%-0.005+114%0.057-33%0.059-35%
Usd Free Cash Flow To Equity Per Share---0.027-0.0270%0.001-3131%-0.008-69%-0.009-68%
Usd Price Per Share0.252-17%0.2960.2960%0.229+29%0.236+25%0.315-6%
Usd Profit--3080658.0003080658.0000%-9011349.000+393%2052722.400+50%4392084.000-30%
Usd Revenue--205266336.000205266336.0000%189957387.000+8%252471841.800-19%233448779.333-12%
Usd Total Gains Per Share--0.0150.0150%-0.040+371%0.010+54%0.067-78%
 EOD+3 -2MRQTTM+0 -0YOY+31 -95Y+26 -1510Y+20 -21

3.2. Fundamental Score

Let's check the fundamental score of Nectar Lifesciences Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1518.355
Price to Book Ratio (EOD)Between0-10.423
Net Profit Margin (MRQ)Greater than00.015
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.462
Current Ratio (MRQ)Greater than11.350
Debt to Asset Ratio (MRQ)Less than10.545
Debt to Equity Ratio (MRQ)Less than11.198
Return on Equity (MRQ)Greater than0.150.023
Return on Assets (MRQ)Greater than0.050.010
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Nectar Lifesciences Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose20.750
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets23,908,320
Total Liabilities13,029,270
Total Stockholder Equity10,879,050
 As reported
Total Liabilities 13,029,270
Total Stockholder Equity+ 10,879,050
Total Assets = 23,908,320

Assets

Total Assets23,908,320
Total Current Assets13,548,490
Long-term Assets13,548,490
Total Current Assets
Cash And Cash Equivalents 157,790
Short-term Investments 4,600
Net Receivables 4,469,780
Inventory 7,212,600
Other Current Assets 66,180
Total Current Assets  (as reported)13,548,490
Total Current Assets  (calculated)11,910,950
+/- 1,637,540
Long-term Assets
Property Plant Equipment 7,651,750
Intangible Assets 430,210
Long-term Assets  (as reported)0
Long-term Assets  (calculated)8,081,960
+/- 8,081,960

Liabilities & Shareholders' Equity

Total Current Liabilities10,038,330
Long-term Liabilities-
Total Stockholder Equity10,879,050
Total Current Liabilities
Short-term Debt 5,027,690
Total Current Liabilities  (as reported)10,038,330
Total Current Liabilities  (calculated)5,027,690
+/- 5,010,640
Long-term Liabilities
Long term Debt Total 2,910,750
Long term Debt 2,907,990
Capital Lease Obligations Min Short Term Debt-5,027,690
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)791,050
+/- 791,050
Total Stockholder Equity
Common Stock224,260
Retained Earnings 7,366,810
Capital Surplus 3,287,980
Total Stockholder Equity (as reported)10,879,050
Total Stockholder Equity (calculated)10,879,050
+/-0
Other
Cash And Equivalents10
Cash and Short Term Investments 162,400
Common Stock Shares Outstanding 224,261
Liabilities and Stockholders Equity 23,908,320



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
23,940,660
24,296,880
25,563,320
25,809,110
27,238,200
27,049,880
26,333,080
23,881,140
23,908,320
23,908,32023,881,14026,333,08027,049,88027,238,20025,809,11025,563,32024,296,88023,940,660
   > Total Current Assets 
12,373,350
13,690,110
14,644,160
14,958,570
16,606,070
16,690,300
16,151,580
12,388,280
13,548,490
13,548,49012,388,28016,151,58016,690,30016,606,07014,958,57014,644,16013,690,11012,373,350
       Cash And Cash Equivalents 
99,780
-10
-10
131,810
-10
212,890
212,935
238,650
157,790
157,790238,650212,935212,890-10131,810-10-1099,780
       Short-term Investments 
3,140
4,350
5,230
4,080
5,100
5,060
1,660
4,570
4,600
4,6004,5701,6605,0605,1004,0805,2304,3503,140
       Net Receivables 
4,564,620
4,464,960
4,914,470
4,997,300
6,119,700
5,587,320
3,958,720
3,748,260
4,469,780
4,469,7803,748,2603,958,7205,587,3206,119,7004,997,3004,914,4704,464,9604,564,620
       Inventory 
7,584,270
8,493,600
8,889,690
9,108,820
9,175,080
9,733,700
10,080,850
6,553,220
7,212,600
7,212,6006,553,22010,080,8509,733,7009,175,0809,108,8208,889,6908,493,6007,584,270
       Other Current Assets 
121,540
63,480
62,470
72,780
99,780
144,130
109,960
69,780
66,180
66,18069,780109,960144,13099,78072,78062,47063,480121,540
   > Long-term Assets 
0
0
0
10,820,460
10,632,130
10,359,580
10,181,500
0
0
0010,181,50010,359,58010,632,13010,820,460000
       Property Plant Equipment 
10,698,070
10,250,430
9,369,360
9,259,110
9,062,170
8,851,860
8,606,550
8,321,530
7,651,750
7,651,7508,321,5308,606,5508,851,8609,062,1709,259,1109,369,36010,250,43010,698,070
       Long Term Investments 
500
1,500
2,700
2,700
0
0
0
0
0
000002,7002,7001,500500
       Intangible Assets 
0
797,560
679,950
574,430
459,240
391,820
391,910
383,640
430,210
430,210383,640391,910391,820459,240574,430679,950797,5600
       Long-term Assets Other 
0
0
0
2,170
5,000
4,990
5,020
0
0
005,0204,9905,0002,170000
> Total Liabilities 
14,670,040
15,276,590
16,022,510
15,742,350
16,651,600
15,998,270
14,971,830
13,260,840
13,029,270
13,029,27013,260,84014,971,83015,998,27016,651,60015,742,35016,022,51015,276,59014,670,040
   > Total Current Liabilities 
11,260,660
11,562,610
12,399,490
12,786,590
13,093,210
12,999,050
12,478,910
11,873,920
10,038,330
10,038,33011,873,92012,478,91012,999,05013,093,21012,786,59012,399,49011,562,61011,260,660
       Short-term Debt 
8,584,180
5,952,980
6,272,430
6,303,410
6,340,830
6,359,690
6,197,130
7,120,040
5,027,690
5,027,6907,120,0406,197,1306,359,6906,340,8306,303,4106,272,4305,952,9808,584,180
       Short Long Term Debt 
8,584,180
9,247,770
9,621,100
8,781,050
7,349,780
7,378,610
6,572,820
0
0
006,572,8207,378,6107,349,7808,781,0509,621,1009,247,7708,584,180
       Accounts payable 
4,400,610
4,555,770
4,967,810
5,280,980
5,394,240
4,836,740
5,271,450
0
0
005,271,4504,836,7405,394,2405,280,9804,967,8104,555,7704,400,610
       Other Current Liabilities 
465,200
333,900
112,480
187,200
230,280
664,480
529,430
0
0
00529,430664,480230,280187,200112,480333,900465,200
   > Long-term Liabilities 
0
0
0
2,955,770
3,558,400
2,999,200
2,492,930
0
0
002,492,9302,999,2003,558,4002,955,770000
       Long term Debt Total 
0
2,655,290
2,453,970
1,638,000
2,200,760
1,655,900
1,214,820
1,282,380
2,910,750
2,910,7501,282,3801,214,8201,655,9002,200,7601,638,0002,453,9702,655,2900
       Capital Lease Obligations 
0
0
0
0
8,300
6,850
0
0
0
0006,8508,3000000
       Long-term Liabilities Other 
0
0
0
185,780
173,800
119,230
22,880
0
0
0022,880119,230173,800185,780000
       Deferred Long Term Liability 
80
359,120
0
0
0
0
0
0
0
0000000359,12080
> Total Stockholder Equity
9,270,620
9,020,290
9,540,810
10,066,760
10,586,600
11,051,610
11,361,250
10,620,300
10,879,050
10,879,05010,620,30011,361,25011,051,61010,586,60010,066,7609,540,8109,020,2909,270,620
   Common Stock
224,260
224,260
224,260
224,260
224,260
224,260
224,260
224,260
224,260
224,260224,260224,260224,260224,260224,260224,260224,260224,260
   Retained Earnings 
5,758,380
6,067,240
6,028,570
6,554,520
7,074,360
7,539,370
7,849,010
7,108,060
7,366,810
7,366,8107,108,0607,849,0107,539,3707,074,3606,554,5206,028,5706,067,2405,758,380
   Capital Surplus 
0
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,9803,287,9803,287,9803,287,9803,287,9803,287,9803,287,9803,287,9800
   Treasury Stock000000000
   Other Stockholders Equity 
0
10
0
0
0
10,827,350
0
0
0
00010,827,350000100



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue16,688,320
Cost of Revenue-13,695,050
Gross Profit2,993,2702,993,270
 
Operating Income (+$)
Gross Profit2,993,270
Operating Expense--
Operating Income1,015,7202,993,270
 
Operating Expense (+$)
Research Development-
Selling General Administrative1,407,870
Selling And Marketing Expenses-
Operating Expense-1,407,870
 
Net Interest Income (+$)
Interest Income680,570
Interest Expense--
Net Interest Income-680,570
 
Pretax Income (+$)
Operating Income1,015,720
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)340,8001,015,720
EBIT - interestExpense = 0
250,460
250,460
Interest Expense-
Earnings Before Interest and Taxes (ebit)-340,800
Earnings Before Interest and Taxes (ebitda)-
 
After tax Income (+$)
Income Before Tax340,800
Tax Provision-90,340
Net Income From Continuing Ops-250,460
Net Income250,460
Net Income Applicable To Common Shares250,470
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
NGU24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGU24-NYM.COMM.

NGU24-NYM.COMM Daily Candlestick Chart
NGM24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGM24-NYM.COMM.

NGM24-NYM.COMM Daily Candlestick Chart
NGQ24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGQ24-NYM.COMM.

NGQ24-NYM.COMM Daily Candlestick Chart
ISKJ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ISKJ.MCX.

ISKJ.MCX Daily Candlestick Chart
CHKZ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CHKZ.MCX.

CHKZ.MCX Daily Candlestick Chart
VSYD.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VSYD.MCX.

VSYD.MCX Daily Candlestick Chart
VRSB.MCX
2 hours ago

I found you a Golden Cross on the daily chart of VRSB.MCX.

VRSB.MCX Daily Candlestick Chart
TBRU.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBRU.MCX.

TBRU.MCX Daily Candlestick Chart
SNGSP.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SNGSP.MCX.

SNGSP.MCX Daily Candlestick Chart
RBCM.MCX
2 hours ago

I found you a Golden Cross on the daily chart of RBCM.MCX.

RBCM.MCX Daily Candlestick Chart
OKEY.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of OKEY.MCX.

OKEY.MCX Daily Candlestick Chart
MTLR.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MTLR.MCX.

MTLR.MCX Daily Candlestick Chart
MRKZ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MRKZ.MCX.

MRKZ.MCX Daily Candlestick Chart
KRKN.MCX
2 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of KRKN.MCX.

KRKN.MCX Daily Candlestick Chart
JNOS.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JNOS.MCX.

JNOS.MCX Daily Candlestick Chart
BLNG.MCX
2 hours ago

I found you a Golden Cross on the daily chart of BLNG.MCX.

BLNG.MCX Daily Candlestick Chart
ASSB.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ASSB.MCX.

ASSB.MCX Daily Candlestick Chart
CSYZ.MU
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CSYZ.MU.

CSYZ.MU Daily Candlestick Chart
MOH.MU
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MOH.MU.

MOH.MU Daily Candlestick Chart
TBK.V
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBK.V.

TBK.V Daily Candlestick Chart
UMDK.F
3 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of UMDK.F.

UMDK.F Daily Candlestick Chart
RY4C.BE
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of RY4C.BE.

RY4C.BE Daily Candlestick Chart
PLY.BE
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PLY.BE.

PLY.BE Daily Candlestick Chart
PDL.LSE
3 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PDL.LSE.

PDL.LSE Daily Candlestick Chart
27F0.MU
3 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of 27F0.MU.

27F0.MU Daily Candlestick Chart